Piper Sandler Companies (PIPR) Stock Analysis and Metrics

Piper Sandler Companies

NYSE: PIPR

$74.93 ▲ +2.95 (+4.11%)

At close: Jul 14, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap4.90 Bn

P/E15.05

P/S2.43

Div. Yield0.03

ROIC (Qtr)0.00

Total Debt (Qtr)15.00 Mn

Revenue Growth (1y) (Qtr)32.99

Add ratio to table…

About

Piper Sandler Companies is an investment bank and institutional securities firm that serves corporations, private equity groups, public entities, non-profit entities, and institutional investors in the United States and internationally. The firm offers a broad range of products and services including financial advisory, equity and debt capital markets, public finance, institutional brokerage, fundamental equity and macro research, fixed income solutions, and alternative asset management strategies. Headquartered in Minneapolis, Minnesota, Piper Sandler maintains offices across the United States and in international locations such as London, Aberdeen, Munich, Paris, Zurich, Abu Dhabi Global Markets, and Hong Kong.

Piper Sandler Companies generates revenue primarily through advisory fees for mergers and acquisitions, equity and debt financings, and private placements. It earns underwriting commissions from municipal bond issuances and debt capital markets activities. The firm receives trading commissions and spreads from institutional brokerage in equities and fixed income, as well as fees from research services provided to investors. Asset management fees from its alternative asset management funds in merchant banking and healthcare also contribute to revenue. Its client base includes corporations, private equity sponsors, governmental bodies, non-profit organizations, banks, registered investment advisors, insurance companies, and other institutional investors.

The company operates through the following segment:

• Investment Banking, Institutional Sales and Trading, and Research: This segment provides investment banking services, institutional sales and trading services for various equity and fixed income products, and research services.

Piper Sandler Companies competes in a highly fragmented securities industry against large Wall Street firms, international banks, regional broker dealers, boutique advisory houses, and alternative trading platforms. Competitive advantages stem from its deep sector expertise across healthcare, financial services, technology, energy, consumer, and industrials, as well as its extensive relationships with middle market clients. The firm leverages the experience of its professionals, including 187 investment banking managing directors as of December 31, 2025, to deliver tailored solutions. As of December 31, 2025, the firm employed 1,858 full-time staff, with 1,735 based in the United States and 123 located in the United Kingdom, Germany, France, Switzerland, and Hong Kong, and approximately 1,400 held FINRA registration. Its integrated platform that combines advisory, sales, trading, and research capabilities allows it to capture more value from client relationships. Additionally, Piper Sandler emphasizes a collaborative culture and strong employee retention programs to sustain its human capital advantage.

Piper Sandler Companies serves a diverse customer base that includes corporations seeking mergers and acquisitions or capital raising, private equity funds pursuing portfolio investments, public entities requiring municipal finance advisory, non-profit organizations needing funding solutions, and institutional investors looking for equity and fixed income execution. The firm also provides services to banks, registered investment advisors, credit unions, asset managers, and insurance companies for fixed income sales, trading, and portfolio management. While specific customer names are not disclosed in the filing, the breadth of its client pipeline reflects its focus on middle market and specialty sectors across North America and Europe.

Investment Thesis

▲ Bull case

PIPR's Healthcare franchise is demonstrating exceptional and sustainable growth beyond a one-time quarterly surge, as evidenced by its record-breaking performance in medtech and biopharma M&A where it ranked as the top adviser by number of announced deals in U.S. medtech M&A and #2 in biopharma equity book-running, driven by deep sector expertise built over a decade across banking, research, capital markets, and sales capabilities that position the firm to capture increasing market share as healthcare innovation accelerates; this structural advantage is reinforced by the successful $85 million Series C financing led by Piper Sandler Merchant Banking for CereVasc, a clinical-stage medical device company, which highlights the firm's ability to originate and execute high-value growth equity transactions in cutting-edge neurology treatments, creating a self-reinforcing cycle where successful deals attract more innovative clients seeking Piper Sandler's specialized healthcare network and execution prowess. The firm's strategic expansion into distressed debt and special assets through the hiring of John Mori and Eric Friel as managing directors represents an underappreciated catalyst that directly addresses current market volatility and regulatory shifts creating dislocation in credit markets, allowing PIPR to monetize opportunities in distressed assets, trade and insurance claims, and reorganized equity that competitors may overlook, while leveraging its existing fixed income, investment banking, and restructuring teams to create a comprehensive platform that appeals to institutional clients seeking nuanced solutions during economic stress, thereby diversifying revenue streams beyond traditional advisory and capital markets activities that are more sensitive to equity market cycles. PIPR's Services and Industrials investment banking division is poised for accelerated growth following the appointment of Rob Parker and Tripp Griffin as co-heads, building on the team's existing scale and momentum with financial sponsors, as highlighted by Matt Sznewajs and John Tye's leadership in growing the firm's largest private equity-focused industry team, which currently represents roughly half of advisory revenue, and the concurrent elevation of Sznewajs, Tye, and David Lee to lead private equity advisory efforts signals a deliberate strategy to deepen penetration with sponsor clients who are increasingly active in services and industrials sectors, creating cross-selling opportunities that enhance client retention and wallet share while reducing dependence on cyclical M&A activity in more volatile sectors like technology or energy. Despite management's cautious commentary on sustaining Q1 Healthcare equity capital markets performance, the underlying fundamentals remain strong with the equity underwriting market showing a 73% year-over-year fee pool increase driven by Healthcare sector activity, and PIPR's completion of 36 equity, debt, and preferred financings raising $14 billion for corporate clients—including 23 equity deals led by its Healthcare team as bookrunner—indicates robust client demand that is not solely dependent on quarterly market share fluctuations but rather reflects enduring confidence in the firm's distribution capabilities and relationships with biopharma issuers, suggesting that any sequential decline in corporate financing revenues will be moderated by persistent structural growth in healthcare innovation financing needs.

PIPR's Healthcare franchise is demonstrating exceptional and sustainable growth beyond a one-time quarterly surge, as evidenced by its record-breaking performance in medtech and biopharma M&A where it ranked as the top adviser by number of announced deals in U.S. medtech M&A and #2 in biopharma equity book-running, driven by deep sector expertise built over a decade across banking, research, capital markets, and sales capabilities that position the firm to capture increasing market share as healthcare innovation accelerates; this structural advantage is reinforced by the successful $85 million Series C financing led by Piper Sandler Merchant Banking for CereVasc, a clinical-stage medical device company, which highlights the firm's ability to originate and execute high-value growth equity transactions in cutting-edge neurology treatments, creating a self-reinforcing cycle where successful deals attract more innovative clients seeking Piper Sandler's specialized healthcare network and execution prowess. The firm's strategic expansion into distressed debt and special assets through the hiring of John Mori and Eric Friel as managing directors represents an underappreciated catalyst that directly addresses current market volatility and regulatory shifts creating dislocation in credit markets, allowing PIPR to monetize opportunities in distressed assets, trade and insurance claims, and reorganized equity that competitors may overlook, while leveraging its existing fixed income, investment banking, and restructuring teams to create a comprehensive platform that appeals to institutional clients seeking nuanced solutions during economic stress, thereby diversifying revenue streams beyond traditional advisory and capital markets activities that are more sensitive to equity market cycles. PIPR's Services and Industrials investment banking division is poised for accelerated growth following the appointment of Rob Parker and Tripp Griffin as co-heads, building on the team's existing scale and momentum with financial sponsors, as highlighted by Matt Sznewajs and John Tye's leadership in growing the firm's largest private equity-focused industry team, which currently represents roughly half of advisory revenue, and the concurrent elevation of Sznewajs, Tye, and David Lee to lead private equity advisory efforts signals a deliberate strategy to deepen penetration with sponsor clients who are increasingly active in services and industrials sectors, creating cross-selling opportunities that enhance client retention and wallet share while reducing dependence on cyclical M&A activity in more volatile sectors like technology or energy. Despite management's cautious commentary on sustaining Q1 Healthcare equity capital markets performance, the underlying fundamentals remain strong with the equity underwriting market showing a 73% year-over-year fee pool increase driven by Healthcare sector activity, and PIPR's completion of 36 equity, debt, and preferred financings raising $14 billion for corporate clients—including 23 equity deals led by its Healthcare team as bookrunner—indicates robust client demand that is not solely dependent on quarterly market share fluctuations but rather reflects enduring confidence in the firm's distribution capabilities and relationships with biopharma issuers, suggesting that any sequential decline in corporate financing revenues will be moderated by persistent structural growth in healthcare innovation financing needs.

▼ Bear case

PIPR's Fixed Income business faces structural headwinds that management understated, as the reliance on balance sheet restructuring trades tied to bank M&A closings to offset reduced regular-way client activity reveals a tactical workaround rather than sustainable demand, with Debbra Schoneman explicitly acknowledging that sustained reduction in market volatility is necessary to revive client participation, and the near-term outlook remains challenging due to ongoing geopolitical developments keeping clients on the sidelines, suggesting that the 6% year-over-year growth in fixed income revenues is fragile and contingent on episodic M&A-related activity rather than organic trading demand, which could reverse if bank M&A announcement volume fails to accelerate as Chad Abraham noted it is 'a little slower than anticipated' in larger transactions. The company's compensation ratio improvement of 90 basis points to 61.6% is partially misleading due to the exclusion of an $8.5 million litigation-related expense tied to the California lawsuit over variable rate demand notes in Municipal Finance, which inflated non-compensation expenses and masked underlying cost pressures; when this non-recurring item is excluded, non-compensation costs rose only 4% year-over-year, but the lingering legal liability from a 2014-filed case indicates ongoing regulatory and compliance risks in the Municipal Finance business that could resurface with additional settlements or judgments, particularly as governmental and specialty municipal financing revenues declined 9% year-over-year to $24 million, signaling weakening demand in a traditionally stable revenue stream. Advisory revenue sustainability is overstated by management's reliance on non-M&A components like Debt Capital Markets Advisory and Private Capital Advisory, which Chad Abraham acknowledged were 'fine' but not the 'outsized performance' driver in Q1, revealing that the record Advisory revenues of $251 million were disproportionately dependent on transient strengths in Healthcare and Financial Services M&A that are difficult to repeat, as evidenced by his statement that 'some of that is just relative to our own performance' and the expectation that Q2 advisory revenues will be 'similar to the first quarter' only under favorable conditions, with no clear pipeline visibility beyond near-term deal flows that remain sensitive to sponsor transaction timing and macroeconomic certainty. The firm's aggressive capital return strategy—returning $171 million to shareholders in Q1 via $101 million in dividends and $70 million in share repurchases—risks overextending financial flexibility given the highly variable compensation model and the acknowledgment that leverage opportunities from revenue growth may be 'more modest' than elsewhere, while the 14% dividend increase to $0.20 per share commits to higher ongoing payouts during a period when Debbra Schoneman admitted fixed income results are 'negatively impacted' by volatility and Equity Brokerage revenues are expected to 'decline from record first quarter levels,' creating potential tension between shareholder returns and the need to reinvest in talent acquisition and technology upgrades amid emerging AI disruption concerns in Software M&A that Chad Abraham conceded will impact the business despite its smaller relative size.

PIPR's Fixed Income business faces structural headwinds that management understated, as the reliance on balance sheet restructuring trades tied to bank M&A closings to offset reduced regular-way client activity reveals a tactical workaround rather than sustainable demand, with Debbra Schoneman explicitly acknowledging that sustained reduction in market volatility is necessary to revive client participation, and the near-term outlook remains challenging due to ongoing geopolitical developments keeping clients on the sidelines, suggesting that the 6% year-over-year growth in fixed income revenues is fragile and contingent on episodic M&A-related activity rather than organic trading demand, which could reverse if bank M&A announcement volume fails to accelerate as Chad Abraham noted it is 'a little slower than anticipated' in larger transactions. The company's compensation ratio improvement of 90 basis points to 61.6% is partially misleading due to the exclusion of an $8.5 million litigation-related expense tied to the California lawsuit over variable rate demand notes in Municipal Finance, which inflated non-compensation expenses and masked underlying cost pressures; when this non-recurring item is excluded, non-compensation costs rose only 4% year-over-year, but the lingering legal liability from a 2014-filed case indicates ongoing regulatory and compliance risks in the Municipal Finance business that could resurface with additional settlements or judgments, particularly as governmental and specialty municipal financing revenues declined 9% year-over-year to $24 million, signaling weakening demand in a traditionally stable revenue stream. Advisory revenue sustainability is overstated by management's reliance on non-M&A components like Debt Capital Markets Advisory and Private Capital Advisory, which Chad Abraham acknowledged were 'fine' but not the 'outsized performance' driver in Q1, revealing that the record Advisory revenues of $251 million were disproportionately dependent on transient strengths in Healthcare and Financial Services M&A that are difficult to repeat, as evidenced by his statement that 'some of that is just relative to our own performance' and the expectation that Q2 advisory revenues will be 'similar to the first quarter' only under favorable conditions, with no clear pipeline visibility beyond near-term deal flows that remain sensitive to sponsor transaction timing and macroeconomic certainty. The firm's aggressive capital return strategy—returning $171 million to shareholders in Q1 via $101 million in dividends and $70 million in share repurchases—risks overextending financial flexibility given the highly variable compensation model and the acknowledgment that leverage opportunities from revenue growth may be 'more modest' than elsewhere, while the 14% dividend increase to $0.20 per share commits to higher ongoing payouts during a period when Debbra Schoneman admitted fixed income results are 'negatively impacted' by volatility and Equity Brokerage revenues are expected to 'decline from record first quarter levels,' creating potential tension between shareholder returns and the need to reinvest in talent acquisition and technology upgrades amid emerging AI disruption concerns in Software M&A that Chad Abraham conceded will impact the business despite its smaller relative size.

Peer Comparison

Companies in the Capital Markets

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	MS	Morgan Stanley	330.70 Bn	0.00 Bn	4.50	119.83 Bn
2	GS	Goldman Sachs Group Inc	309.79 Bn	0.00 Bn	5.12	259.45 Bn
3	SCHW	Schwab Charles Corp	167.21 Bn	0.00 Bn	6.74	-
4	FUTU	Futu Holdings Ltd	111.36 Bn	85.66 Bn	82.13	0.01 Bn
5	HOOD	Robinhood Markets, Inc.	97.69 Bn	0.00 Bn	21.18	-
6	LPLA	LPL Financial Holdings Inc.	23.49 Bn	0.00 Bn	1.29	-
7	TW	Tradeweb Markets Inc.	21.59 Bn	0.00 Bn	9.99	-
8	CRCL	Circle Internet Group, Inc.	15.14 Bn	0.00 Bn	6.85	-

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2016)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2016)

Peer Comparison

Create an account

Sign In

Reset Password